Intellectual Property India Publishes Patent Application for 'Glycosynthase Variants For Antibody-Drug Conjugate Engineering' Filed by Obi Pharma, Inc.

MUMBAI, India, May 30 -- Intellectual Property India has published a patent application (202517043953 A) filed by Obi Pharma, Inc., Taipei City, Taiwan, on May 6, for 'glycosynthase variants for antibody-drug conjugate engineering.'

Inventor(s) include Lai, Ming-Tain; Chou, Jun-Hong; Hsieh, Yin-Cheng; Huang, Teng-Yi; Huang, Chen-Ping; Fung, Ka-Shu; and Hsia, Chi-Sheng.

The application for the patent was published on May 30, under issue no. 22/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure relates to novel glycosynthase enzymes for antibody-drug conjugates (ADCs) engineering. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification a...